SCI Pharmtech, Inc. (TPE:4119)

Market Cap	9.32B
Revenue (ttm)	1.52B
Net Income (ttm)	534.68M
Shares Out	119.51M
EPS (ttm)	4.46
PE Ratio	17.49
Forward PE	50.98
Dividend	1.50 (1.93%)
Ex-Dividend Date	n/a

Volume	67,481
Average Volume	154,345
Open	77.60
Previous Close	77.60
Day's Range	77.60 - 78.50
52-Week Range	77.10 - 98.50
Beta	-0.09
RSI	15.28
Earnings Date	Mar 18, 2025

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2024, SCI Pharmtech's revenue was 1.52 billion, an increase of 26.54% compared to the previous year's 1.20 billion. Earnings were 534.68 million, an increase of 81.42%.